# Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

> **NCT00258427** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 14 (actual)

## Conditions studied

- Fanconi Anemia

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** filgrastim
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **DRUG:** methylprednisolone
- **BIOLOGICAL:** Hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00258427
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03-26
- **Primary completion:** 2020-10-10
- **Final completion:** 2020-10-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258427, "Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00258427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*